Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Weekend catch-up sleep can cut diabetes risk
Two consecutive nights of “catch up” sleep on the weekend may reverse the increased risk of diabetes associated with short-term sleep deficit during the work week, suggests new research.
- Read more about Novel nanotherapy may beat antibiotic-resistant superbugs
A novel light-activated nanotherapy developed by researchers at the University of Colorado- Boulder may be an effective weapon against the drug-resistant bacteria, say researchers including one of Indian-origin.
- Read more about Cranberry can help fight urinary tract infections in babies
Cranberry extracts can help fighting urinary tract infections (UTIs) or bladder infection in breast-fed babies less than one year of age, new research says

[adsense:336x280:8701650588]
- Read more about Green vegetable intake can cut glaucoma risk
Greater intake of dietary nitrate and green leafy vegetables is associated with a 20-30 percent lower risk of primary open-angle glaucoma (POAG), according to a study.
- Read more about BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an etanercept biosimilar referencing Enbrel®. BENEPALI has been granted marketing authorization in the European Union (EU) for the treatment of adults with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis. Biogen intends to make BENEPALI available for patients in the coming weeks.
- Read more about FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter to the Company's New Drug Application (NDA) for KyndrisaTM (drisapersen) for the treatment of Duchenne muscular dystrophy (Duchenne) amenable to exon 51 skipping.
amenable to exon
- Read more about Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in PVNS
Five Prime Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for FPA008 for the treatment of Pigmented Villonodular Synovitis (PVNS), a locally aggressive tumor of the synovium.
- Read more about Impax Receives Approval of EMVERM™ (mebendazole) Chewable Tablets, 100 mg
Impax Laboratories, Inc. announced that the United States Food and Drug Administration (FDA) has approved the Company's supplemental new drug application (sNDA) for EMVERM (mebendazole) 100 mg chewable tablets
- Read more about FDA clears Olympus TJF-Q180V duodenoscope with design modifications to reduce infection risk
The US Food and Drug Administration cleared the Olympus TJF-Q180V duodenoscope with modifications to the device’s design and labeling intended to help reduce the risk of bacterial infections. Olympus will voluntarily recall its original model currently being used in health care facilities and make the needed repair as quickly as possible.
- Read more about Heron Therapeutics Notified by FDA
Heron Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has not yet completed its review of the New Drug Application (NDA) of SUSTOL® (granisetron) Injection,extended release and would not be taking action by the Prescription Drug User Fee Act (PDUFA) goal date of January 17, 2016 and anticipates taking action in late February 2016.